Critical Survey: Biolife Solutions (BLFS) & Viewray (VRAY)

Biolife Solutions (NASDAQ: BLFS) and Viewray (NASDAQ:VRAY) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Biolife Solutions and Viewray, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biolife Solutions 0 0 3 0 3.00
Viewray 0 0 5 0 3.00

Biolife Solutions currently has a consensus target price of $8.50, suggesting a potential downside of 4.71%. Viewray has a consensus target price of $11.90, suggesting a potential upside of 67.37%. Given Viewray’s higher possible upside, analysts clearly believe Viewray is more favorable than Biolife Solutions.

Insider and Institutional Ownership

11.9% of Biolife Solutions shares are owned by institutional investors. Comparatively, 83.4% of Viewray shares are owned by institutional investors. 38.5% of Biolife Solutions shares are owned by company insiders. Comparatively, 62.8% of Viewray shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Biolife Solutions and Viewray’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Biolife Solutions $11.02 million 11.45 -$2.51 million ($0.21) -42.48
Viewray $34.04 million 14.98 -$72.17 million ($1.04) -6.84

Biolife Solutions has higher earnings, but lower revenue than Viewray. Biolife Solutions is trading at a lower price-to-earnings ratio than Viewray, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Biolife Solutions has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500. Comparatively, Viewray has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500.

Profitability

This table compares Biolife Solutions and Viewray’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Biolife Solutions -13.17% -18.99% -15.72%
Viewray -83.09% -1,375.57% -44.36%

Summary

Viewray beats Biolife Solutions on 8 of the 13 factors compared between the two stocks.

About Biolife Solutions

BioLife Solutions, Inc. develops, manufactures, and markets patented tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, and delayed-onset cell damage and death. The company offers HypoThermosol FRS, a hypothermic storage and shipping media product to mitigate temperature-induced molecular cell stress responses that occur during chilling and re-warming of biologics, intermediate products, and final cell products intended for research and clinical applications; and CryoStor cryopreservation freeze media products to mitigate temperature-induced molecular cell stress responses during freezing and thawing. It also provides BloodStor freeze media products, such as BloodStor 55-5 and BloodStor 100 for cryopreservation of stem and other cells isolated from umbilical cord and peripheral blood, and bone marrow; and cell thawing media, which offers Dextran and saline for washing cryopreserved cells and tissues to dilute or remove cryoprotectants. In addition, the company provides custom product formulation and packaging services; and contract aseptic manufacturing formulation, filling, and finishing services for liquid media products. It markets its products to the regenerative medicine, bio-banking, and drug discovery markets, including hospital-based stem cell transplant centers, pharmaceutical companies, cord blood and adult stem cell banks, and hair transplant centers, as well as suppliers of cells to the drug discovery, toxicology testing, and diagnostic markets. The company markets and sells its products directly using its sales force, as well as through biolifesolutions.com; and through various regional distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.

About Viewray

ViewRay, Inc. designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. MRIdian delivers radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian provides real-time imaging that defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription between fractions as needed.

Receive News & Ratings for Biolife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biolife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply